Precision Ultrasound Shows Promise for Organ-Preserving Prostate Cancer Therapy

A multicenter study in Austria has demonstrated that MRI-guided high-intensity focused ultrasound (HIFU) can effectively treat early prostate cancer while preserving urinary and sexual function. Conducted across three hospitals under Karl Landsteiner University of Health Sciences (KL Krems), the trial enrolled 51 men with low- to intermediate-risk localized prostate cancer between 2021 and 2024.

Patients underwent lesion-specific HIFU ablation and were followed for two years with PSA testing, MRI scans, and biopsies. Tumor control was achieved in over 80% of participants, with 94% requiring no additional therapy. PSA levels dropped by 69% within three months and remained stable. Adverse events were mild and transient, and erectile function fully recovered within 6–12 months, while urinary function improved or remained stable.

The study highlights focal HIFU as a feasible, organ-preserving alternative to radical surgery or radiotherapy, supporting its integration into clinical practice and paving the way for more personalized prostate cancer treatment strategies in Austria.

25-11-2025